GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Beneish M-Score

Radiopharm Theranostics (ASX:RAD) Beneish M-Score : -4.32 (As of Sep. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.32 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Radiopharm Theranostics's Beneish M-Score or its related term are showing as below:

ASX:RAD' s Beneish M-Score Range Over the Past 10 Years
Min: -4.32   Med: -4.32   Max: -4.32
Current: -4.32

During the past 3 years, the highest Beneish M-Score of Radiopharm Theranostics was -4.32. The lowest was -4.32. And the median was -4.32.


Radiopharm Theranostics Beneish M-Score Historical Data

The historical data trend for Radiopharm Theranostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Beneish M-Score Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24
Beneish M-Score
- - -4.32

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beneish M-Score Get a 7-Day Free Trial - - - - -4.32

Competitive Comparison of Radiopharm Theranostics's Beneish M-Score

For the Biotechnology subindustry, Radiopharm Theranostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Beneish M-Score falls into.



Radiopharm Theranostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Radiopharm Theranostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.2157+0.528 * 1+0.404 * 0.8725+0.892 * 1.024+0.115 * 0.9989
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1414+4.679 * -0.199678-0.327 * 1.3823
=-4.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Total Receivables was A$0.99 Mil.
Revenue was A$0.30 Mil.
Gross Profit was A$0.30 Mil.
Total Current Assets was A$22.85 Mil.
Total Assets was A$72.04 Mil.
Property, Plant and Equipment(Net PPE) was A$0.06 Mil.
Depreciation, Depletion and Amortization(DDA) was A$3.13 Mil.
Selling, General, & Admin. Expense(SGA) was A$15.22 Mil.
Total Current Liabilities was A$17.58 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.
Net Income was A$-47.95 Mil.
Gross Profit was A$-10.59 Mil.
Cash Flow from Operations was A$-22.98 Mil.
Total Receivables was A$4.47 Mil.
Revenue was A$0.29 Mil.
Gross Profit was A$0.29 Mil.
Total Current Assets was A$16.30 Mil.
Total Assets was A$74.95 Mil.
Property, Plant and Equipment(Net PPE) was A$0.07 Mil.
Depreciation, Depletion and Amortization(DDA) was A$3.30 Mil.
Selling, General, & Admin. Expense(SGA) was A$13.02 Mil.
Total Current Liabilities was A$13.23 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.987 / 0.299) / (4.468 / 0.292)
=3.301003 / 15.30137
=0.2157

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.292 / 0.292) / (0.299 / 0.299)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (22.848 + 0.061) / 72.036) / (1 - (16.3 + 0.068) / 74.95)
=0.681978 / 0.781614
=0.8725

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.299 / 0.292
=1.024

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.297 / (3.297 + 0.068)) / (3.126 / (3.126 + 0.061))
=0.979792 / 0.98086
=0.9989

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(15.218 / 0.299) / (13.021 / 0.292)
=50.896321 / 44.592466
=1.1414

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 17.576) / 72.036) / ((0 + 13.229) / 74.95)
=0.243989 / 0.176504
=1.3823

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-47.949 - -10.589 - -22.976) / 72.036
=-0.199678

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Radiopharm Theranostics has a M-score of -4.32 suggests that the company is unlikely to be a manipulator.


Radiopharm Theranostics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics Business Description

Traded in Other Exchanges
N/A
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics Headlines

No Headlines